Pattern of drug resistant Helicobacter pylori in dyspeptic patients in Thailand

Journal of the Medical Association of Thailand

Volumn 86, Issue SUPPL. 2, 2003, Pages

  Tangmankongworakoon, Nathaya ^a   Thong Ngam, Duangporn ^a   Tumwasorn, Somying ^a   Mahachai, Varocha ^a   Vilaichone, Ratha Korn ^a   Kullavanijaya, Pinit ^a  

^a KING CHULALONGKORN MEMORIAL HOSPITAL   (Thailand)

Author keywords

Drug Resistance; Dyspeptic Patients; Helicobacter Pylori; Thailand

Indexed keywords

AMOXICILLIN; CLARITHROMYCIN; METRONIDAZOLE; TETRACYCLINE; UREASE;

ADULT; AGE DISTRIBUTION; AGED; ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIUM CULTURE; BACTERIUM DETECTION; BACTERIUM ISOLATION; CONTROLLED STUDY; DRUG EFFICACY; DUODENUM ULCER; DYSPEPSIA; FEMALE; GASTROINTESTINAL ENDOSCOPY; HELICOBACTER PYLORI; HUMAN; MAJOR CLINICAL STUDY; MALE; MULTIDRUG RESISTANCE; PREVALENCE; SEX DIFFERENCE; STOMACH BIOPSY; STOMACH ULCER; THAILAND;

ADULT; AGED; AGED, 80 AND OVER; DRUG RESISTANCE, BACTERIAL; DYSPEPSIA; FEMALE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; MALE; MIDDLE AGED; THAILAND;

EID: 0042432020     PISSN: 01252208     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Marshall BJ. Helicobacter pylori. Am J Gastroenterol 1994; 89 (8 Suppl):S116-28.
2. Rauws EA, Tytgat GN. Cure of duodenal ulcer associated with eradication of Helicobacter pylori. Lancet 1990, 26; 335: 1233-5.
3. Asghar RJ, Parsonnet J. Helicobacter pylori and risk for gastric adenocarcinoma. Semin Gastrointest Dis 2001; 12: 203-8
4. Sipponen P. Gastric cancer: Pathogenesis, risks, and prevention. J Gastroenterol 2002; 37 (Suppl 13): 39-44.
5. Megraud F. Antibiotic resistance in Helicobacter pylori infection. Br Med Bull 1998; 54: 207-16.
6. Graham DY. Antibiotic resistance in Helicobacter pylori: Implications for therapy. Gastroenterology 1998; 115: 1272-7.
7. Goodwin CS. Antimicrobial treatment of Helicobacter pylori infection. Clin Infect Dis 1997; 25: 1023-6.
8. Katelaris PH, Nguyen TV, Robertson GJ, Bradbury R, Ngu MC. Prevalence and demographic determinants of metronidazole resistance by Helicobacter pylori in a large cosmopolitan cohort of Australian dyspeptic patients. Aust N Z J Med 1998; 28: 633-8.
9. Peitz U, Hackelsberger A, Malfertheiner P. A practical approach to patients with refractory Helicobacter pylori infection, or who are re-infected after standard therapy. Drugs 1999; 57: 905-20.
10. Segura AM, Gutierrez O, Otero W, Angel A, Genta RM, Graham DY. Furazolidone, amoxicillin, bismuth triple therapy for Helicobacter pylori infection. Aliment Pharmacol Ther 1997; 11: 529-32.
11. 2 receptor antagonist therapy for Helicobacter pylori peptic ulcer disease in Korea. Aliment Pharmacol Ther 1997; 11: 939-42.
12. Alarcon T, Domingo D, Lopez-Brea M. Antibiotic resistance problems with Helicobacter pylori. Int J Antimicrob Agents 1999; 12: 19-26.
13. van Zwet AA, de Boer WA, Schneeberger PM, Weel J, Jansz AR, Thijs JC. Prevalence of primary Helicobacter pylori resistance to metronidazole and clarithromycin in the Netherlands. Eur J Clin Microbiol Infect Dis 1996; 15: 861-4.
14. Wolle K, Nilius M, Leodolter A, et al. Prevalence of primary Helicobacter pylori resistance to several antimicrobial agents in a region of Germany. Eur J Clin Microbiol Infect Dis 1998; 17: 519-21.
15. Osato MS, Reddy R, Graham DY. Metronidazole and clarithromycin resistance amongst Helicobacter-pylori isolates from a large metropolitan hospital in the United States. Int J Antimicrob Agents 1999; 12: 341-7.
16. Vakil N, Hahn B, McSorley D. Clarithromycin: resistant Helicobacter pylori in patients with duodenal ulcer in the United States. Am J Gastroenterol 1998; 93: 1432-5.
17. Meyer JM, Silliman NP, Wang W, Siepman NY, Sugg JE, Morris D. Risk factors for Helicobacter pylori Resistance in the United States: The surveillance of H. pylori antimicrobial resistance partnership (SHARP) Study, 1993-1999. Ann Intern Med 2002; 136: 13-24.
18. Glupczynski Y. Antimicrobial resistance in Helicobacter pylori: A global overview. Acta Gastroenterol Belg 1998; 61: 357-66.
19. Broutet N, Guillon F, Sauty E, Lethuaire D, Megraud F. Survey of the in vitro susceptibility of Helicobacter pylori to antibiotics in France-Preliminary results. Gut 1998; 43 (Suppl 2): A11.
20. Vasquez A, Valdez Y, Gilman RH. Metronidazole resistance in Helicobacter pylori determined by measuring MICs of antimicrobial agents in color indicator egg yolk agar in a miniwell format. J Clin Microbiol 1996; 34: 1232-4.
21. Rozynek E, Dziersanowska D, Celinska-Cedro D, Jeljaszewicz J. Primary resistance to metronidazole and other antibiotics of Helicobacter pylori isolated from children in Poland. Eur J Clin Microbiol Infect Dis 1997; 16: 943-4.
22. Meyer JM, Higgins KM, Wang W. Evaluation of risk factors in the surveillance of H. pylori antimicrobial resistance partnership (SHARP) in the United States from 1993-1999. Gastroenterology 2000; 118: A677.
23. Wang WH, Wong BCY, Mukhopadhyay AK. High prevalence of Helicobacter pylori infection with dual resistance to metronidazole and clarithromycin in Hong Kong. Aliment Pharmacol Ther 2000; 14: 901-10.
24. Kato M, Yamaoka Y, Kim JJ. Regional differences in metronidazole resistance and increasing clarithromycin resistance among Helicobacter pylori isolates from Japan. Antimicrob Agents Chemother 2000; 44: 2214-6.